Business Description
PCI Biotech Holding ASA
NAICS : 325412
SIC : 2834
ISIN : NO0010405640
Total Employee Number:
7Compare
Compare
Traded in other countries / regions
PCIB.Norway0JGL.UK4QG.GermanyPCIBO.Sweden IPO Date
2008-06-18Description
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 48.29 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.8 | |||||
3-Year EPS without NRI Growth Rate | 43 | |||||
3-Year FCF Growth Rate | 41.4 | |||||
3-Year Book Growth Rate | -40.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.02 | |||||
9-Day RSI | 24.7 | |||||
14-Day RSI | 33.17 | |||||
3-1 Month Momentum % | -26.12 | |||||
6-1 Month Momentum % | -42.54 | |||||
12-1 Month Momentum % | -86.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.94 | |||||
Quick Ratio | 2.94 | |||||
Cash Ratio | 2.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 3.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -90.78 | |||||
ROA % | -70.7 | |||||
ROIC % | -374.25 | |||||
3-Year ROIIC % | -388.79 | |||||
ROC (Joel Greenblatt) % | -2025.52 | |||||
ROCE % | -90 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.21 | |||||
Price-to-Tangible-Book | 0.21 | |||||
EV-to-EBIT | 0.52 | |||||
EV-to-EBITDA | 0.53 | |||||
EV-to-FCF | 0.65 | |||||
| Price-to-Net-Current-Asset-Value | 0.23 | |||||
| Price-to-Net-Cash | 0.36 | |||||
Earnings Yield (Greenblatt) % | 192.31 | |||||
FCF Yield % | -611.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PCI Biotech Holding ASA Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.55 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.97 | ||
| 3-Year Sortino Ratio | -1.11 | ||
| Volatility % | 86.38 | ||
| 14-Day RSI | 33.17 | ||
| 14-Day ATR (kr) | 0.030133 | ||
| 20-Day SMA (kr) | 0.15995 | ||
| 12-1 Month Momentum % | -86.08 | ||
| 52-Week Range (kr) | 0.09 - 2.22 | ||
| Shares Outstanding (Mil) | 37.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PCI Biotech Holding ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PCI Biotech Holding ASA Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-28 08:30 | In 56 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 07:00 | In 56 days | ||
| General meeting for 2026 | 2026-05-22 10:00 | 0.13 (-11.19%) | ||
| Annual report for 2025 | 2026-05-15 | 0.13 (-11.19%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-05-13 08:30 | 0.13 (-11.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-05-13 | 0.13 (-11.19%) | ||
| Annual report for 2025 | 2026-05-08 | 0.13 (-11.19%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-05-06 08:30 | 0.13 (-11.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-05-06 | 0.13 (-11.19%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-29 08:30 | 0.40 (-5.95%) |
Show
Entries
PCI Biotech Holding ASA Frequently Asked Questions
What is PCI Biotech Holding ASA(OSL:PCIB)'s stock price today?
The current price of OSL:PCIB is kr0.12. The 52 week high of OSL:PCIB is kr2.22 and 52 week low is kr0.09.
When is next earnings date of PCI Biotech Holding ASA(OSL:PCIB)?
The next earnings date of PCI Biotech Holding ASA(OSL:PCIB) is 2026-08-28 Est..
Does PCI Biotech Holding ASA(OSL:PCIB) pay dividends? If so, how much?
PCI Biotech Holding ASA(OSL:PCIB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on PCI Biotech Holding ASA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers